$2.38
+0.00 (+0.00%)
Open$2.37
Previous Close$2.38
Day High$2.41
Day Low$2.29
52W High$3.23
52W Low$0.95
Volume—
Avg Volume1.78M
Market Cap279.18M
P/E Ratio—
EPS$-1.05
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+141.6% upside
Current
$2.38
$2.38
Target
$5.75
$5.75
$4.43
$5.75 avg
$6.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.42M | 15.66M | 39.14M |
| Net Income | -131,835,850 | -289,254,668 | -10,010,485 |
| Profit Margin | -2,051.1% | -1,948.5% | -25.6% |
| EBITDA | -130,376,751 | -301,945,181 | -16,322,152 |
| Free Cash Flow | — | — | -10,981,777 |
| Rev Growth | -59.0% | -59.0% | +22.5% |
| Debt/Equity | 0.05 | 0.05 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |